{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:49:41Z","timestamp":1774550981584,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.ppat.1014026","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000}}],"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI38709"],"award-info":[{"award-number":["AI38709"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001906","name":"Washington Research Foundation","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100001906","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>A growing body of evidence underscores the role of antibody-dependent cellular cytotoxicity (ADCC) in antiviral immunity. Yet, the mechanisms underlying the ability of certain antibodies (Abs) to mediate potent ADCC activity remain poorly characterized. In particular the contribution of features within the antigen-binding Fab region remains largely unexplored. In this study, we leveraged a collection of 142 SARS-CoV-2 monoclonal Abs to systematically dissect the determinants of ADCC activity. We analyzed their epitope domain target, binding characteristics, neutralization potency, somatic hypermutation (SHM) and CDR3 length to determine the contribution of these features to ADCC activity. We found that ADCC activity is primarily shaped by epitope target - particularly targeting of the S2 domain of the Spike glycoprotein. ADCC potency was not associated with the degree of SHM or neutralization. Notably, ADCC activity was not correlated with binding activity and moderate binding to antigen was sufficient for ADCC activity. By integrating these analyses, we provide a comprehensive framework for understanding the molecular and functional determinants of ADCC. Together, these findings offer novel insights into the mechanisms that underpin ADCC functions, with implications for vaccine design and therapeutic Abs development.<\/jats:p>","DOI":"10.1371\/journal.ppat.1014026","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:36:52Z","timestamp":1773337012000},"page":"e1014026","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of natural killer cell-mediated antibody dependent cellular cytotoxicity in SARS-CoV-2 antibodies"],"prefix":"10.1371","volume":"22","author":[{"given":"Delphine M.","family":"Depierreux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Guenthoer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrasha","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-9444","authenticated-orcid":true,"given":"Julie","family":"Overbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"7","key":"ppat.1014026.ref001","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41577-020-0359-5","article-title":"Dissecting antibody-mediated protection against SARS-CoV-2","volume":"20","author":"T Zohar","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6251","key":"ppat.1014026.ref002","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/342803a0","article-title":"Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells","volume":"342","author":"LL Lanier","year":"1989","journal-title":"Nature"},{"issue":"10","key":"ppat.1014026.ref003","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.141.10.3478","article-title":"Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes","volume":"141","author":"LL Lanier","year":"1988","journal-title":"J Immunol"},{"issue":"6","key":"ppat.1014026.ref004","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1073\/pnas.87.6.2274","article-title":"Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells","volume":"87","author":"P Anderson","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ppat.1014026.ref005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"F Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"7158","key":"ppat.1014026.ref006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature06106","article-title":"Fc receptor but not complement binding is important in antibody protection against HIV","volume":"449","author":"AJ Hessell","year":"2007","journal-title":"Nature"},{"issue":"14","key":"ppat.1014026.ref007","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"ppat.1014026.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074855","article-title":"High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers","volume":"8","author":"O Lambotte","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"ppat.1014026.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002739","article-title":"HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads","volume":"8","author":"J Mabuka","year":"2012","journal-title":"PLoS Pathog"},{"key":"ppat.1014026.ref010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by Antibodies: Recent Progress","volume":"35","author":"S Bournazos","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"ppat.1014026.ref011","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.chom.2015.03.002","article-title":"Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality","volume":"17","author":"C Milligan","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"10","key":"ppat.1014026.ref012","doi-asserted-by":"crossref","first-page":"100428","DOI":"10.1016\/j.xcrm.2021.100428","article-title":"HIV-1 protection: Antibodies move in for the kill","volume":"2","author":"ZA Yaffe","year":"2021","journal-title":"Cell Rep Med"},{"issue":"4","key":"ppat.1014026.ref013","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.xcrm.2021.100254","article-title":"Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts","volume":"2","author":"ZA Yaffe","year":"2021","journal-title":"Cell Rep Med"},{"issue":"6","key":"ppat.1014026.ref014","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"S Bournazos","year":"2014","journal-title":"Cell"},{"issue":"2","key":"ppat.1014026.ref015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"DJ DiLillo","year":"2016","journal-title":"J Clin Invest"},{"issue":"11","key":"ppat.1014026.ref016","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"EO Saphire","year":"2018","journal-title":"Nat Immunol"},{"issue":"9","key":"ppat.1014026.ref017","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"I Ullah","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"ppat.1014026.ref018","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-021-00759-1","article-title":"Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients","volume":"6","author":"Y Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ppat.1014026.ref019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"A Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"10","key":"ppat.1014026.ref020","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiac060","article-title":"Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination","volume":"225","author":"GJ Rieke","year":"2022","journal-title":"J Infect Dis"},{"issue":"15","key":"ppat.1014026.ref021","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170681","article-title":"Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2","volume":"8","author":"MD Grant","year":"2023","journal-title":"JCI Insight"},{"issue":"12","key":"ppat.1014026.ref022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"K Tao","year":"2021","journal-title":"Nat Rev Genet"},{"issue":"5","key":"ppat.1014026.ref023","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01647-22","article-title":"Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity","volume":"13","author":"KA Bowman","year":"2022","journal-title":"mBio"},{"issue":"7","key":"ppat.1014026.ref024","doi-asserted-by":"crossref","first-page":"110368","DOI":"10.1016\/j.celrep.2022.110368","article-title":"A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection","volume":"38","author":"G Beaudoin-Bussi\u00e8res","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"ppat.1014026.ref025","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.10.052","article-title":"Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality","volume":"183","author":"T Zohar","year":"2020","journal-title":"Cell"},{"issue":"7815","key":"ppat.1014026.ref026","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"D Pinto","year":"2020","journal-title":"Nature"},{"issue":"1","key":"ppat.1014026.ref027","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"JB Case","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"ppat.1014026.ref028","article-title":"The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody","volume":"16","author":"CEZ Chan","year":"2021","journal-title":"PLoS One"},{"issue":"15","key":"ppat.1014026.ref029","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","article-title":"SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2","volume":"184","author":"F Amanat","year":"2021","journal-title":"Cell"},{"issue":"9","key":"ppat.1014026.ref030","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.cell.2021.03.028","article-title":"N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2","volume":"184","author":"M McCallum","year":"2021","journal-title":"Cell"},{"issue":"3","key":"ppat.1014026.ref031","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"AJ Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"5","key":"ppat.1014026.ref032","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"G Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"7839","key":"ppat.1014026.ref033","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"CO Barnes","year":"2020","journal-title":"Nature"},{"issue":"7898","key":"ppat.1014026.ref034","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"issue":"2","key":"ppat.1014026.ref035","doi-asserted-by":"crossref","first-page":"100510","DOI":"10.1016\/j.xcrm.2022.100510","article-title":"SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity","volume":"3","author":"SI Richardson","year":"2022","journal-title":"Cell Rep Med"},{"issue":"6","key":"ppat.1014026.ref036","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.xcrm.2021.100290","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"SP Anand","year":"2021","journal-title":"Cell Rep Med"},{"issue":"642","key":"ppat.1014026.ref037","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn9243","article-title":"Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines","volume":"14","author":"YC Bartsch","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"ppat.1014026.ref038","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jsb.2016.02.001","article-title":"Structural characterization of GASDALIE Fc bound to the activating Fc receptor Fc\u03b3RIIIa","volume":"194","author":"AA Ahmed","year":"2016","journal-title":"J Struct Biol"},{"issue":"7","key":"ppat.1014026.ref039","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"ES Winkler","year":"2021","journal-title":"Cell"},{"issue":"7885","key":"ppat.1014026.ref040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","article-title":"Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy","volume":"599","author":"R Yamin","year":"2021","journal-title":"Nature"},{"key":"ppat.1014026.ref041","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"KO Saunders","year":"2019","journal-title":"Front Immunol"},{"issue":"42","key":"ppat.1014026.ref042","doi-asserted-by":"crossref","first-page":"11931","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"W He","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"ppat.1014026.ref043","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220948120","article-title":"Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection","volume":"120","author":"J Guenthoer","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ppat.1014026.ref044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012650","article-title":"Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses","volume":"20","author":"F Ruiz","year":"2024","journal-title":"PLoS Pathog"},{"issue":"8","key":"ppat.1014026.ref045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012383","article-title":"The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2","volume":"20","author":"J Guenthoer","year":"2024","journal-title":"PLoS Pathog"},{"key":"ppat.1014026.ref046","article-title":"Re-infection with SARS-CoV-2 is associated with increased antibody breadth and potency against diverse sarbecovirus strains","author":"M Lilly","year":"2026","journal-title":"mBio"},{"issue":"10","key":"ppat.1014026.ref047","article-title":"Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody","volume":"9","author":"Y-H Chang","year":"2024","journal-title":"JCI Insight"},{"issue":"7","key":"ppat.1014026.ref048","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"WT Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"ppat.1014026.ref049","doi-asserted-by":"crossref","first-page":"1266829","DOI":"10.3389\/fimmu.2023.1266829","article-title":"Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1","volume":"14","author":"CA Balinsky","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"ppat.1014026.ref050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"L Piccoli","year":"2020","journal-title":"Cell"},{"issue":"10","key":"ppat.1014026.ref051","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.4049\/jimmunol.1601473","article-title":"Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms","volume":"198","author":"KLS Cleary","year":"2017","journal-title":"J Immunol"},{"issue":"2","key":"ppat.1014026.ref052","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.01.001","article-title":"mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern","volume":"55","author":"P Kaplonek","year":"2022","journal-title":"Immunity"},{"issue":"12","key":"ppat.1014026.ref053","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01523-25","article-title":"Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions","volume":"99","author":"K Muthuraman","year":"2025","journal-title":"J Virol"},{"key":"ppat.1014026.ref054","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63444","article-title":"Development of antibody-dependent cell cytotoxicity function in HIV-1 antibodies","volume":"10","author":"LE Doepker","year":"2021","journal-title":"Elife"},{"issue":"4","key":"ppat.1014026.ref055","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.xpro.2021.100851","article-title":"A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells","volume":"2","author":"G Beaudoin-Bussi\u00e8res","year":"2021","journal-title":"STAR Protoc"},{"issue":"22","key":"ppat.1014026.ref056","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1128\/JVI.75.22.11096-11105.2001","article-title":"Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion","volume":"75","author":"CM Finnegan","year":"2001","journal-title":"J Virol"},{"issue":"7874","key":"ppat.1014026.ref057","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","article-title":"Broad sarbecovirus neutralization by a human monoclonal antibody","volume":"597","author":"MA Tortorici","year":"2021","journal-title":"Nature"},{"issue":"1","key":"ppat.1014026.ref058","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.11.012","article-title":"D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization","volume":"29","author":"D Weissman","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6483","key":"ppat.1014026.ref059","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"D Wrapp","year":"2020","journal-title":"Science"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1014026","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:50:06Z","timestamp":1774547406000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1014026"}},"subtitle":[],"editor":[{"given":"Christopher F.","family":"Basler","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1014026","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}